Japan Approves SIGA Technologies Antiviral

SIGA’s antiviral approved in Japan for orthopoxvirus treatment
The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical antiviral treatme
Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox
On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment TEPOXX (tecovirimat 200 mg capsules) for smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg.
SIGA's Tepoxx Gets Regulatory Approval In Japan For Treatment Of Orthopoxviruses
(RTTNews) - SIGA Technologies, Inc. (SIGA), Thursday announced that its tecovirimat 200 mg capsules, traded as TEPOXX, has secured regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg.
SIGA wins Japan approval for mpox therapy Tepoxx
SIGA Technologies (NASDAQ:SIGA) announced Thursday that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved its antiviral product Tepoxx (tecovirimat) for the treatment of orthopoxviruses,
SIGA Technologies receives Japanese approval for Tepoxx for the treatment of orthopoxviruses
SIGA Technologies receives Japanese approval for Tepoxx for the treatment of orthopoxviruses: New York Saturday, January 4, 2025, 12:00 Hrs [IST] SIGA Technologies, a commercial s
news.stocktradersdaily8d
(SIGA) Trading Advice
Trading Advice for Siga Technologies Inc. SIGA including day trading swing trading and long term investing plans for SIGA ...
Ghanaweb.com12d
Prioritise operations of SIGA to address inefficiencies in SEs – John Boadu to incoming government
John Boadu, Director General (DG) of the State Interests and Governance Authority (SIGA), has called on the incoming ...
Morningstar3d
SIGA Technologies Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...